2 stories mentioning SVRAUpdated 85d ago
Every FINWIRES story that references SVRA, newest first.
David L Lowrance, Chief Financial Officer, on June 22, 2026, sold 394,528 shares in Savara (SVRA) for $2,241,432. Following the Form 4 filing with the SEC, Lowrance has control over a total of 536,032 common shares of the company, with 536,032 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1160308/000119312526278061/xslF345X05/ownership.xml
Savara (SVRA) said late Wednesday the US Food and Drug Administration has extended the review period for molgramostim biologics license application in autoimmune pulmonary alveolar proteinosis, a rare lung disease, by three months.The new prescription drug user fee act target action date for the inhalation solution is Nov. 22, the company said.The FDA did not cite any efficacy, safety, or manufacturing concerns, the company said, adding that the FDA determined that the responses to recent information requests represented a significant amendment to the application.
